BRPI0609636B8 - formulação oral de liberação modificada que compreende um agente ativo e um revestimento entérico - Google Patents

formulação oral de liberação modificada que compreende um agente ativo e um revestimento entérico

Info

Publication number
BRPI0609636B8
BRPI0609636B8 BRPI0609636A BRPI0609636A BRPI0609636B8 BR PI0609636 B8 BRPI0609636 B8 BR PI0609636B8 BR PI0609636 A BRPI0609636 A BR PI0609636A BR PI0609636 A BRPI0609636 A BR PI0609636A BR PI0609636 B8 BRPI0609636 B8 BR PI0609636B8
Authority
BR
Brazil
Prior art keywords
active agent
enteric coating
modified release
oral formulation
release oral
Prior art date
Application number
BRPI0609636A
Other languages
English (en)
Inventor
M Davila Claudia
Leblond David
Y Lee Dennis
R Engh Kevin
E Gustavson Linda
C Jayaraman Shyamala
Zhu Tong
R Ju Tzuchi
Gao Yi
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0609636A2 publication Critical patent/BRPI0609636A2/pt
Publication of BRPI0609636B1 publication Critical patent/BRPI0609636B1/pt
Publication of BRPI0609636B8 publication Critical patent/BRPI0609636B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

formulações farmacêuticas a presente invenção diz respeito às tormulações orais que compreendem um agente ativo compreendendo pelo menos um de ácido 2-[4- (4-clorobenzoil) fenóxi]-2-metil-propanóico, sais de ácido 2-4-(4-clorobenzoil) fenóxi]-2-metil-propanóico ou ácido 2-[4-(4-clorobenzoil) fenóxi]-2-metil-propanóico tamponado.
BRPI0609636A 2005-04-08 2006-04-07 formulação oral de liberação modificada que compreende um agente ativo e um revestimento entérico BRPI0609636B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66969905P 2005-04-08 2005-04-08
US60/669,699 2005-04-08
PCT/US2006/013121 WO2006135480A2 (en) 2005-04-08 2006-04-07 Oral pharmaceutical formulations comprising fenofibric acid and/or its salts

Publications (3)

Publication Number Publication Date
BRPI0609636A2 BRPI0609636A2 (pt) 2009-09-29
BRPI0609636B1 BRPI0609636B1 (pt) 2020-12-29
BRPI0609636B8 true BRPI0609636B8 (pt) 2021-05-25

Family

ID=37246305

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609636A BRPI0609636B8 (pt) 2005-04-08 2006-04-07 formulação oral de liberação modificada que compreende um agente ativo e um revestimento entérico

Country Status (16)

Country Link
US (4) US20070264334A1 (pt)
EP (2) EP2074992B1 (pt)
JP (1) JP5114382B2 (pt)
KR (1) KR20080008352A (pt)
CN (2) CN101217944A (pt)
AU (1) AU2006258217A1 (pt)
BR (1) BRPI0609636B8 (pt)
CA (1) CA2604078C (pt)
EA (1) EA023376B1 (pt)
ES (1) ES2545589T3 (pt)
IL (1) IL186435A (pt)
MX (1) MX2007012443A (pt)
NO (1) NO343548B1 (pt)
SG (1) SG161256A1 (pt)
UA (1) UA100966C2 (pt)
WO (1) WO2006135480A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
CN101480384A (zh) * 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
WO2007052592A1 (ja) * 2005-10-31 2007-05-10 Kowa Co., Ltd. 光安定性に優れた医薬製剤
US7915247B1 (en) 2006-08-21 2011-03-29 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
KR20090119959A (ko) * 2006-10-12 2009-11-23 아보트 러보러터리즈 약학적 제형
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
EP2083799A1 (en) * 2006-10-20 2009-08-05 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
GB2465896B (en) * 2007-01-29 2011-12-07 Teraview Ltd A pharmaceutical analysis method and apparatus
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
WO2009085766A2 (en) * 2007-12-19 2009-07-09 Mutual Pharmaceutical Company, Inc. Fenofibric acid amorphous dispersion; method of making; and method of use thereof
CN101951902A (zh) * 2008-02-28 2011-01-19 诺瓦提斯公司 缬沙坦固体口服剂型以及制备该制剂的方法
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CN101590239B (zh) * 2008-05-30 2013-03-27 北京奥萨医药研究中心有限公司 含有利尿剂、他汀和叶酸的药物组合物及其用途
US20110123575A1 (en) * 2008-06-02 2011-05-26 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
DE102008030046A1 (de) * 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
CN101744786B (zh) * 2008-12-17 2012-11-14 南京星银药业集团有限公司 一种非洛地平缓释片处方及制备方法
CN102341103A (zh) * 2009-01-02 2012-02-01 爱尔兰福尼雅实验室有限公司 贝特类的新用途
TR201111143T1 (tr) * 2009-05-11 2012-05-21 Lupin Limited Yeni̇ farmasöti̇k koli̇n fenofi̇brat bi̇leşi̇mleri̇
EP2521537A2 (en) * 2010-01-04 2012-11-14 Wockhardt Limited Pharmaceutical composition for modified delivery of actives
KR101202994B1 (ko) 2010-04-12 2012-11-21 한미사이언스 주식회사 페노피브린산 및 알칼리화제를 포함하는 경구용 약학 조성물
WO2011154013A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibric acid
CN102058544B (zh) * 2010-12-10 2012-10-03 山东省医药工业研究所 非诺贝特酸胆碱盐肠溶缓释微丸的制备方法
CN102757338B (zh) * 2012-02-29 2015-02-25 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途
EP2958548A1 (en) * 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A production process for gliclazide formulations
CN104758293A (zh) * 2014-01-02 2015-07-08 江苏吉贝尔药业有限公司 一种新的复方抗高血压制剂的制备方法
CN105748445A (zh) * 2016-03-31 2016-07-13 武汉药谷生物工程有限公司 一种非诺贝酸胆碱缓释胶囊的制备方法
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂
EP3664782B1 (en) * 2017-08-09 2025-01-29 Albireo AB Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
CN109369425B (zh) * 2018-11-05 2022-01-04 陕西威信制药有限公司 非诺贝特酸胆碱盐的制备方法
KR102501636B1 (ko) * 2021-12-07 2023-02-21 에이스바이오팜 주식회사 페노피브린산을 포함하는 경구용 정제 및 이의 제조방법
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (pt) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541003A (en) 1968-03-06 1970-11-17 Gulf Research Development Co Two-phase vortex reaction-separation system
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
GB1415295A (en) * 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
US3907792A (en) 1969-01-31 1975-09-23 Andre Mieville Phenoxy-alkyl-carboxylic acid derivatives and the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
US5776935A (en) * 1996-07-25 1998-07-07 Merz & Co. Gmbh & Co. Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
SK8792002A3 (en) * 1999-12-23 2003-05-02 Astrazeneca Ab Quinoline-based compound, pharmaceutical composition containing same and use thereof
AU2001272262A1 (en) * 2000-07-07 2002-01-21 Kemestrie Inc. Drug delivery system for poorly water soluble drugs
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2002254056C1 (en) * 2001-03-02 2006-04-13 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
CN101480384A (zh) * 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
EP1621200A1 (en) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate

Also Published As

Publication number Publication date
US20060280791A1 (en) 2006-12-14
EP1868587A2 (en) 2007-12-26
CA2604078A1 (en) 2006-12-21
EP2074992B1 (en) 2015-05-20
BRPI0609636A2 (pt) 2009-09-29
ES2545589T3 (es) 2015-09-14
KR20080008352A (ko) 2008-01-23
JP5114382B2 (ja) 2013-01-09
UA100966C2 (ru) 2013-02-25
WO2006135480A2 (en) 2006-12-21
NO20075628L (no) 2007-11-05
EA023376B1 (ru) 2016-05-31
EA200702198A1 (ru) 2008-04-28
CN101217944A (zh) 2008-07-09
US20060280790A1 (en) 2006-12-14
IL186435A0 (en) 2008-01-20
US20070264334A1 (en) 2007-11-15
EP2074992A1 (en) 2009-07-01
IL186435A (en) 2015-09-24
JP2008535851A (ja) 2008-09-04
CA2604078C (en) 2013-07-23
WO2006135480A9 (en) 2007-02-15
CN102172347A (zh) 2011-09-07
US20070128278A1 (en) 2007-06-07
HK1131918A1 (en) 2010-02-12
BRPI0609636B1 (pt) 2020-12-29
MX2007012443A (es) 2007-12-13
AU2006258217A1 (en) 2006-12-21
SG161256A1 (en) 2010-05-27
WO2006135480A3 (en) 2007-04-05
NO343548B1 (no) 2019-04-01

Similar Documents

Publication Publication Date Title
BRPI0609636B8 (pt) formulação oral de liberação modificada que compreende um agente ativo e um revestimento entérico
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CL2013002251A1 (es) Composicion de cosmético que comprende un compuesto de silicio y un ingrediente del cuidado personal; emulsión acuosa y no acuosa. (divisional solicitud 893-2007)
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
ATE464902T1 (de) Stabile pharmazeutische zubereitungen von montelukast-natrium
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
NO20083104L (no) Fast preparat
AR055838A1 (es) Formulaciones para microproyecciones recubiertas que tienen solubilidad controlada
BRPI0511707A (pt) peroxifosfatos de cálcio e sua utilização em composições dentais
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
WO2008020314A3 (en) Statin stabilizing dosage formulations
UY31059A1 (es) Formulaciones de aminoacido n-halogenado
UY31058A1 (es) Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
UA94955C2 (en) Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl] benzoic acid
CL2007002105A1 (es) Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
BRPI0800753A2 (pt) composiÇÕes contendo retinàide e derivados do Ácido beta-aminoisobutÍrico
ECSP078010A (es) Formulación de liberación prolongada de principios activos que presentan una solubilidad dependiente del ph
ATE472316T1 (de) Haarbehandlungszusammensetzungen
FR2938766B1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat de feuille de vigne (vitis vinifera l.) en tant que principe actif activateur de l'aconitase et protecteur des mitochondries
UY31057A1 (es) Formulaciones de aminoacido n-halogenado que contiene acido alifatico
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
FR2882522B1 (fr) Composition pharmaceutique solide comprenant de la telithromycine
EP4023647A4 (en) IMIDAZOPYRIDINL DERIVATIVES AND PHARMACEUTICAL COMPOSITION WITH THEM AS AN ACTIVE SUBSTANCE
BRPI0921835A2 (pt) formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento.
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 1950, DE 20/05/2008, APRESENTE NOVO DOCUMENTO DE CESSAO, REFERENTE AO PEDIDO PCT/US2006/013121, ENTRE "TONG ZHU" E "ABBOTT LABORATORIES" COM DATA ANTERIOR A DATA DE ENTRADA NA FASE NACIONAL, PARA QUE O REFERIDO PEDIDO SEJA DEVIDAMENTE REGULARIZADO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF